Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0S9SD
|
|||
| Former ID |
DAP001084
|
|||
| Drug Name |
Emtricitabine
|
|||
| Synonyms |
Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis virus infection [ICD-11: 1E50-1E51] | Approved | [1], [2], [3] | |
| Human immunodeficiency virus infection [ICD-11: 1C62] | Approved | [1], [2], [3] | ||
| Hepatitis B virus infection [ICD-11: 1E51.0; ICD-10: B18.1] | Phase 3 | [4] | ||
| Therapeutic Class |
Anti-HIV Agents
|
|||
| Company |
Gilead; Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H10FN3O3S
|
|||
| Canonical SMILES |
C1C(OC(S1)CO)N2C=C(C(=NC2=O)N)F
|
|||
| InChI |
1S/C8H10FN3O3S/c9-4-1-12(8(14)11-7(4)10)5-3-16-6(2-13)15-5/h1,5-6,13H,2-3H2,(H2,10,11,14)/t5-,6+/m0/s1
|
|||
| InChIKey |
XQSPYNMVSIKCOC-NTSWFWBYSA-N
|
|||
| CAS Number |
CAS 143491-57-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
582989, 600446, 7848262, 8187110, 11528728, 12014747, 14749730, 14847619, 24875080, 26757984, 43118210, 46507606, 48424313, 49830960, 50064421, 57314168, 71814561, 76230216, 92308841, 92729801, 99313695, 103232542, 104178758, 104321867, 117506117, 118046007, 118313743, 126592961, 126653602, 126654249, 126665394, 127310207, 127310208, 129727356, 134223773, 134338341, 135018286, 135022892, 135590997, 136947986, 137006539, 142372786, 144205746, 151992517, 152034369, 160826182, 160964220, 162792750, 163388307, 163621100
|
|||
| ChEBI ID |
CHEBI:31536
|
|||
| ADReCS Drug ID | BADD_D00766 | |||
| SuperDrug ATC ID |
J05AF09
|
|||
| SuperDrug CAS ID |
cas=143491570
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Modulator | [1], [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Nat Rev Drug Discov. 2013 Feb;12(2):87-90. | |||
| REF 2 | Emtricitabine: a novel nucleoside reverse transcriptase inhibitor. Drugs Today (Barc). 2005 Apr;41(4):241-52. | |||
| REF 3 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 4 | Clinical pipeline report, company report or official report of Gilead (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.